Drugs / Orvepitant
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04387981 | Jun 2020 | — | Nerre Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03535662 | Jun → Aug 2018 | — | Nerre Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00843011 | Aug → Oct 2008 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00675116 | Apr → Jul 2008 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00511654 | Jun 2007 → Jan 2008 | depressive disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT05185089 | Aug 2022 → Jun 2024 | idiopathic pulmonary fibrosis | Nerre Therapeutics Ltd. | Completed | Missed primary |
| Phase 2 | NCT02993822 | May 2017 → Jan 2019 | — | Nerre Therapeutics Ltd. | Completed | Missed primary |
| Phase 2 | NCT01000493 | Nov 2009 → Jun 2010 | post-traumatic stress disorder | GlaxoSmithKline | Completed | Missed primary |
| Phase 2 | NCT00880048 | Mar 2009 → Jun 2010 | depressive disorder | GlaxoSmithKline | Terminated | Missed primary |
| Phase 2 | NCT00880399 | Mar 2009 → Jun 2010 | major depressive disorder | GlaxoSmithKline | Terminated | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03464526 Comparator | May 2018 → Jun 2019 | atopic eczema | Nerre Therapeutics Ltd. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | orvepitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00880048 ↗ |
| Known as | GW-823296B | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105667 ↗ |
| Known as | GW-823296X | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105667 ↗ |
| Known as | GW823296 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00511654 ↗ |
| Known as | Orvepitant Maleate | “Orvepitant Maleate” NCT05185089 ↗ |
| Action | Inhibit | “neurokinin-1 (NK1) receptor antagonist” NCT00843011 ↗1“Neurokinin 1 receptor antagonist” CHEMBL2105667 ↗ |
| Modality | Small molecule | — CHEMBL2105667 ↗ |
| Route | Oral | “for oral administration” NCT00511654 ↗ |
| Target | TACR1 | “Neurokinin 1 receptor antagonist” CHEMBL2105667 ↗ |